Sejahteraraya Anugrahjaya Tbk PT
The company’s capital structure is highly leveraged, with a debt-to-equity ratio of 0.87, indicating a moderate reliance on debt financing. Liquidity is constrained, as evidenced by a current ratio of 0.4, suggesting that the company may struggle to meet short-term obligations with its current assets. Free cash flow is negative at -71.27 billion IDR, and capital expenditures are substantial at -275.27 billion IDR, indicating ongoing investment in infrastructure or operations. The price-to-book ratio of 91.35 and price-to-tangible-book ratio of 91.35 suggest that the market is valuing the company’s intangible assets at a premium relative to its book value. Profitability metrics are weak, with a return on equity (ROE) of 0.26% and return on assets (ROA) of 0.09%, both significantly below industry norms for healthcare providers. Operating income of 46.77 billion IDR and net income of 4.90 billion IDR indicate a narrow margin of profitability, with a gross profit margin of 30.28% (232.54 billion IDR on 768.29 billion IDR revenue). These figures suggest the company is operating with limited pricing power and high cost structures. Geographic and segment exposure is not explicitly detailed in the available data, but the company’s revenue is concentrated in a single business line, as no segment breakdown is provided. This lack of diversification increases vulnerability to sector-specific shocks. The absence of disclosed geographic revenue distribution also limits visibility into regional risk exposure. Growth trajectory appears muted, with no forward-looking revenue guidance provided in the outlook. Historical revenue of 768.29 billion IDR is the only data point available, and no year-over-year growth rate is disclosed. The company’s high capital expenditures suggest it is investing in expansion, but the negative free cash flow indicates that these investments are not yet generating positive returns. Risk factors include liquidity constraints, as the company’s cash and equivalents (169.93 billion IDR) are insufficient to cover its long-term debt (161.50 billion IDR), resulting in a net cash position that is negative. The risk assessment flags this as a key concern. Dilution risk is currently low, with no significant changes in shares outstanding between basic and diluted shares (12.24 billion shares in both cases). However, the company’s high leverage and negative free cash flow could necessitate future equity or debt financing, which may increase dilution risk. No recent events, such as filings or transcripts, are available in the provided data to inform the company’s strategic direction or operational developments. The absence of recent disclosures limits the ability to assess management’s response to market conditions or regulatory changes.
Business. Sejahteraraya Anugrahjaya Tbk PT operates in the healthcare facilities and services industry, providing biotechnology-related services and equipment, and generates revenue primarily through healthcare service delivery and product sales.
Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.
- The company is highly leveraged, with a debt-to-equity ratio of 0.87 and a negative net cash position.
- Profitability is weak, with ROE and ROA at 0.26% and 0.09%, respectively.
- Liquidity is constrained, as indicated by a current ratio of 0.4 and negative free cash flow.
- The company’s valuation is elevated, with a price-to-book ratio of 91.35.
- Growth is not clearly defined, with no forward-looking revenue guidance provided.
- --
- # RATIONALES
- ```json
- Net cash is negative after subtracting total debt.